上海凯宝(300039) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥307,980,576.42, representing an increase of 18.53% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥60,836,808.13, a significant increase of 69.77% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥60,302,078.04, up 75.27% from the previous year[5] - Total operating revenue for the current period reached ¥1,154,328,501.63, a significant increase from ¥800,013,064.85 in the previous period, representing a growth of approximately 44.3%[20] - Net profit for the current period was ¥195,830,856.66, compared to ¥118,044,013.52 in the previous period, reflecting an increase of approximately 66.1%[21] - Basic and diluted earnings per share increased to ¥0.1875 from ¥0.1134, reflecting a growth of approximately 65.5%[22] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥4,402,537,389.72, reflecting a growth of 3.36% compared to the end of the previous year[5] - Total assets as of September 30, 2023, amounted to CNY 4,402,537,389.72, an increase from CNY 4,259,271,286.92 at the beginning of the year[19] - Total liabilities increased to CNY 580,668,911.42 from CNY 498,240,511.29, reflecting a rise in current liabilities[19] - The total equity attributable to shareholders at the end of Q3 2023 was ¥3,821,549,825.36, a rise of 1.59% from the previous year[5] - The company's total equity as of September 30, 2023, was CNY 3,821,868,478.30, up from CNY 3,761,030,775.63[19] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥289,951,827.18, an increase of 22.70%[5] - Cash flow from operating activities generated a net amount of ¥289,951,827.18, compared to ¥236,316,100.08 in the previous period, an increase of approximately 22.7%[25] - Cash and cash equivalents at the end of the period totaled ¥537,266,310.62, up from ¥261,967,635.68, representing a growth of approximately 105.5%[26] - The company reported a net cash outflow from investing activities of ¥4,405,686.72, compared to a net outflow of ¥197,783,410.48 in the previous period, showing an improvement[25] - The company incurred a total of ¥62,760,000.00 in cash outflows for financing activities, compared to ¥52,300,000.00 in the previous period, representing an increase of approximately 19.1%[25] Research and Development - Research and development expenses increased by 112.59% year-on-year for the first nine months of 2023, indicating a significant investment in innovation[10] - Research and development expenses increased to ¥76,729,257.45 from ¥36,092,230.66, marking a growth of about 112.5%[21] Other Financial Metrics - The company's gross profit margin improved, with operating income for the first nine months of 2023 increasing by 44.29% due to rising market demand[10] - The company reported a 7105.53% increase in credit impairment losses for the first nine months of 2023, attributed to the reversal of bad debt provisions[11] - Total operating costs amounted to ¥927,485,108.17, up from ¥660,043,298.28, indicating a rise of about 40.5%[20] - Total comprehensive income for the current period was ¥122,264,402.67, down from ¥703,354,013.52 in the previous period, indicating a decrease of approximately 82.6%[22] Shareholder Information - The number of common shareholders at the end of the reporting period was 68,852[14] - The top shareholder, Mu Jingwei, holds 16.06% of the shares, totaling 168,029,270 shares[14] Investments - The company has ongoing investments in long-term equity, totaling CNY 7,250,345.66, down from CNY 8,413,013.70[18] - The company reported a significant increase in other receivables, rising to CNY 56,992,863.42 from CNY 35,766,906.83, an increase of approximately 59.5%[18] Audit and Accounting Standards - The third quarter report has not been audited[27] - The new accounting standards were first implemented in 2023, affecting the financial statements from the beginning of the year[27] Corporate Governance - Shanghai Kaibao Pharmaceutical Co., Ltd. held a board meeting on October 17, 2023[28]